Last reviewed · How we verify

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

NCT04712734 PHASE1 COMPLETED

This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.

Details

Lead sponsorVanda Pharmaceuticals
PhasePHASE1
StatusCOMPLETED
Enrolment42
Start dateWed Jan 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionTue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

United States